Interventional nanotheranostics in hepatocellular carcinoma

Interventional nanotheranostics is a system of drug delivery that does a dual function; along with the therapeutic action, it also does have diagnostic features. This method helps in early detection, targeted delivery, and the least chances of damage to surrounding tissue. It ensures the highest efficiency for the management of the disease. Imaging is the near future for the quickest and most accurate detection of disease. After combing both effective measures, it ensures the most meticulous drug delivery system. Nanoparticles such as Gold NPs, Carbon NPs, Silicon NPS, etc. The article emphasizes on effect of this delivery system in the treatment of Hepatocellular Carcinoma. It is one of the widely spreading diseases and theranostics is trying to make the scenario better. The review suggests the pitfall of the current system and how theranostics can help. It describes the mechanism used to generate its effect and believes that interventional nanotheranostics do have a future with rainbow color. The article also describes the current hindrance to the flourishing of this miraculous technology.

[1]  Vivek P. Chavda,et al.  Biodegradable and removable implants for controlled drug delivery and release application , 2022, Expert opinion on drug delivery.

[2]  R. Verma,et al.  Fullerenes for the treatment of cancer: an emerging tool , 2022, Environmental Science and Pollution Research.

[3]  Vivek P. Chavda,et al.  Lyotropic liquid crystals for parenteral drug delivery. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[4]  C. Cristea,et al.  Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma , 2022, Materials.

[5]  D. Janas,et al.  Application of carbon nanotubes in sensing/monitoring of pancreas and liver cancer. , 2022, Chemosphere.

[6]  W. Alshaer,et al.  Liposomes: structure, composition, types, and clinical applications , 2022, Heliyon.

[7]  Vivek P. Chavda,et al.  Phytochemical-loaded liposomes for anticancer therapy: an updated review. , 2022, Nanomedicine.

[8]  Xiao-Yi Chen,et al.  Metal nanoparticles as a promising technology in targeted cancer treatment , 2022, Drug delivery.

[9]  Vivek P. Chavda,et al.  Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines , 2022, Frontiers in Pharmacology.

[10]  W. Wang,et al.  Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives , 2022, Theranostics.

[11]  Ruihang Zhang,et al.  Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer , 2022, International journal of nanomedicine.

[12]  Juan Li,et al.  Graphene-based nanomaterials for cancer therapy and anti-infections , 2022, Bioactive Materials.

[13]  G. Soraya,et al.  Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma , 2022, World journal of gastroenterology.

[14]  M. Bhat,et al.  Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment , 2021, Pharmaceutics.

[15]  S. Gan,et al.  New challenges in the use of nanomedicine in cancer therapy , 2021, Bioengineered.

[16]  C. Allen,et al.  Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes. , 2021, Nanomedicine : nanotechnology, biology, and medicine.

[17]  A. Zamyatnin,et al.  Nanomedicine for increasing the oral bioavailability of cancer treatments , 2021, Journal of Nanobiotechnology.

[18]  Lei Cao,et al.  Engineering nanotheranostic strategies for liver cancer , 2021, World journal of gastrointestinal oncology.

[19]  Vivek P. Chavda,et al.  Role of Data Mining in Bioinformatics , 2021, Computation in Bioinformatics.

[20]  Vivek P. Chavda,et al.  New Bioinformatics Platform‐Based Approach for Drug Design , 2021, Computation in Bioinformatics.

[21]  Vivek P. Chavda,et al.  In Silico Protein Design and Virtual Screening , 2021, Computation in Bioinformatics.

[22]  Vivek P. Chavda,et al.  Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds , 2021, Frontiers in Pharmacology.

[23]  T. Karpiński,et al.  Nanoparticles for Cancer Therapy: Current Progress and Challenges , 2021, Nanoscale Research Letters.

[24]  R. Ullah,et al.  Mild Hyperthermia Responsive Liposomes for Enhanced In Vitro and In Vivo Anticancer Efficacy of Doxorubicin against Hepatocellular Carcinoma , 2021, Pharmaceutics.

[25]  K. Evason,et al.  Exploring the Interplay of Telomerase Reverse Transcriptase and β-Catenin in Hepatocellular Carcinoma , 2021, Cancers.

[26]  V. Torchilin,et al.  Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment , 2021, Journal of personalized medicine.

[27]  Xiangxian Ying,et al.  Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles , 2021, Molecules.

[28]  J. Calderaro,et al.  Pathologic and molecular features of hepatocellular carcinoma: An update , 2021, World journal of hepatology.

[29]  P. Galle,et al.  The Current Landscape of Clinical Trials for Systemic Treatment of HCC , 2021, Cancers.

[30]  S. Beg,et al.  Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting. , 2020, Current Drug Targets.

[31]  Nicholas A. Peppas,et al.  Engineering precision nanoparticles for drug delivery , 2020, Nature reviews. Drug discovery.

[32]  Y. Chang,et al.  Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma , 2020, International journal of molecular sciences.

[33]  Ju Dong Yang,et al.  New advances in the diagnosis and management of hepatocellular carcinoma , 2020, BMJ.

[34]  Yihan Yao,et al.  Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance , 2020, Frontiers in Molecular Biosciences.

[35]  Hang Zhao,et al.  Multifunctional Gold Nanoparticles: A Novel Nanomaterial for Various Medical Applications and Biological Activities , 2020, Frontiers in Bioengineering and Biotechnology.

[36]  A. Lechel,et al.  Telomeres and Telomerase in the Development of Liver Cancer , 2020, Cancers.

[37]  E. D. De Toni,et al.  The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects , 2020, Signal Transduction and Targeted Therapy.

[38]  G. Nagaraju,et al.  Nanotheranostics: Their role in hepatocellular carcinoma. , 2020, Critical reviews in oncology/hematology.

[39]  M. C. Bonferoni,et al.  Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting , 2020, Nanomaterials.

[40]  C. Jasirwan,et al.  The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia , 2020, BMC Gastroenterology.

[41]  Carol S. Lim,et al.  Advances in delivery vectors for gene therapy in liver cancer. , 2019, Therapeutic delivery.

[42]  C. Moonen,et al.  Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo , 2019, Cancers.

[43]  Pedro Pedrosa,et al.  Nanotheranostics Targeting the Tumor Microenvironment , 2019, Front. Bioeng. Biotechnol..

[44]  Y. Greish,et al.  Current status of nanomaterial-based treatment for hepatocellular carcinoma. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[45]  P. Bose,et al.  Advances in early diagnosis of hepatocellular carcinoma , 2019, Hepatoma Research.

[46]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[47]  R. Duran,et al.  Theranostics in Interventional Oncology: Versatile Carriers for Diagnosis and Targeted Image-Guided Minimally Invasive Procedures , 2019, Front. Pharmacol..

[48]  Jingwen Peng,et al.  Progress in research on gold nanoparticles in cancer management , 2019, Medicine.

[49]  P. Sil,et al.  Role of nanostructures in improvising oral medicine , 2019, Toxicology reports.

[50]  Dong-Jin Lim,et al.  Gold Nanoparticles for Photothermal Cancer Therapy , 2019, Front. Chem..

[51]  J. Prados,et al.  Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment , 2019, Nanomaterials.

[52]  Y. Ghasemi,et al.  Gold nanoparticles application in liver cancer. , 2019, Photodiagnosis and photodynamic therapy.

[53]  T. de Baère,et al.  Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.

[54]  M. Bally,et al.  Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response , 2018, International journal of molecular sciences.

[55]  Leonardo Fernandes Fraceto,et al.  Nano based drug delivery systems: recent developments and future prospects , 2018, Journal of Nanobiotechnology.

[56]  Kyoungju Choi,et al.  Assessment of Gold Nanoparticles-Inhibited Cytochrome P450 3A4 Activity and Molecular Mechanisms Underlying Its Cellular Toxicity in Human Hepatocellular Carcinoma Cell Line C3A , 2018, Nanoscale Research Letters.

[57]  Priyanka Singh,et al.  Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer , 2018, International journal of molecular sciences.

[58]  J. Karlsson,et al.  Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments. , 2018, Annual review of chemical and biomolecular engineering.

[59]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[60]  James R. Smith,et al.  Liposomal Drug Delivery Systems and Anticancer Drugs , 2018, Molecules.

[61]  Wei Hu,et al.  Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy , 2018, International journal of nanomedicine.

[62]  Satya Gupta,et al.  Recent advances in carbon nanotube based electrochemical biosensors. , 2018, International journal of biological macromolecules.

[63]  A. Singal,et al.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review , 2017, Journal of clinical and translational hepatology.

[64]  A. Goyal,et al.  Recent advances in metal nanoparticles in cancer therapy , 2017, Journal of drug targeting.

[65]  Xu Li,et al.  Diabetes Mellitus and Risk of Hepatocellular Carcinoma , 2017, BioMed research international.

[66]  K. Sandeep,et al.  Liposomes for Drug Delivery , 2017 .

[67]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[68]  P. Couzigou,et al.  Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma , 2017, ESMO Open.

[69]  Kristofer J. Thurecht,et al.  Bridging Bio-Nano Science and Cancer Nanomedicine. , 2017, ACS nano.

[70]  Qiang Shen,et al.  Cancer drug delivery in the nano era: An overview and perspectives , 2017, Oncology reports.

[71]  Jie Tan,et al.  An ‘activatable’ aptamer-based fluorescence probe for the detection of HepG2 cells , 2017, Oncology reports.

[72]  K. Hynynen,et al.  To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[73]  Shiming Yang,et al.  Current applications and future prospects of nanomaterials in tumor therapy , 2017, International journal of nanomedicine.

[74]  A. R. Fernandes,et al.  Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer—The Case for Combined Delivery? , 2017, Genes.

[75]  A. Yari Khosroushahi,et al.  Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles , 2017, Journal of cellular and molecular medicine.

[76]  Rong Zheng,et al.  Aptamer Combined with Fluorescent Silica Nanoparticles for Detection of Hepatoma Cells , 2017, Nanoscale Research Letters.

[77]  G. Jiang,et al.  Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma. , 2016, Recent patents on anti-cancer drug discovery.

[78]  R. Lencioni,et al.  RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. , 2016, Hepatic oncology.

[79]  N. Fidelman,et al.  Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down‐staging? , 2016, Hepatology.

[80]  H. H. Oh,et al.  Multiple Bone Metastases as the First Manifestation of Hepatocellular Carcinoma in Patient with Noncirrhotic Liver , 2015, Case reports in oncological medicine.

[81]  Wei Guo,et al.  Screening and Identifying a Novel ssDNA Aptamer against Alpha-fetoprotein Using CE-SELEX , 2015, Scientific Reports.

[82]  D. Haemmerich,et al.  Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model , 2015, PloS one.

[83]  Y. Rolland,et al.  Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[84]  M. Owais,et al.  Nano-Sized Drug Delivery Systems: Development and Implication in Treatment of Hepatocellular Carcinoma , 2015, Digestive Diseases.

[85]  Hiroshi Maeda,et al.  Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. , 2015, Advanced drug delivery reviews.

[86]  Min-yan Wei,et al.  Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma , 2015, International journal of nanomedicine.

[87]  A. Kouzani,et al.  Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors , 2015, Theranostics.

[88]  B. Ghosh,et al.  Current trends in using polymer coated gold nanoparticles for cancer therapy. , 2015, International journal of pharmaceutics.

[89]  K. Simon,et al.  Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature , 2015, Case reports in oncological medicine.

[90]  Ji-Ho Park,et al.  Endocytosis and exocytosis of nanoparticles in mammalian cells , 2014, International journal of nanomedicine.

[91]  A. Raza,et al.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine. , 2014, World journal of gastroenterology.

[92]  Yoshito Itoh,et al.  Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. , 2014, World journal of gastroenterology.

[93]  B. Guiu,et al.  Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. , 2013, Critical reviews in oncology/hematology.

[94]  A. K. Kondapi,et al.  A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular Cancer , 2013, Journal of Cancer.

[95]  Zhen Zhang,et al.  Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention , 2013, Oncology letters.

[96]  Qing He,et al.  Transcatheter Arterial Chemoembolization: History for More than 30 Years , 2012, ISRN gastroenterology.

[97]  Gang Liu,et al.  High-sensitivity nanosensors for biomarker detection. , 2012, Chemical Society reviews.

[98]  N. Desai Challenges in Development of Nanoparticle-Based Therapeutics , 2012, The AAPS Journal.

[99]  Seong-Wook Lee,et al.  Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein. , 2012, Biochemical and biophysical research communications.

[100]  J. Bruix,et al.  Management of HCC. , 2012, Journal of hepatology.

[101]  M. Prasanth,et al.  Interventional Radiological Treatment of Hepatocellular Carcinoma: An Update , 2012, Indian Journal of Surgery.

[102]  T. Murakami,et al.  Ultrasonography, Computed Tomography and Magnetic Resonance Imaging of Hepatocellular Carcinoma: Toward Improved Treatment Decisions , 2011, Oncology.

[103]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[104]  Priyabrata Mukherjee,et al.  Gold nanoparticles: opportunities and challenges in nanomedicine , 2010, Expert opinion on drug delivery.

[105]  J. Geschwind,et al.  Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand? , 2010, Annals of Surgical Oncology.

[106]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[107]  J. D. Elliott,et al.  New Strategies in Drug Discovery , 2006, Methods in molecular biology.

[108]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[109]  T. Morgan,et al.  Alcohol and hepatocellular carcinoma. , 2004, Gastroenterology.

[110]  L. Pączek,et al.  [Liver transplantation for hepatocellular carcinoma]. , 2003, Polskie Archiwum Medycyny Wewnetrznej.

[111]  J. Bruix,et al.  Hepatitis B virus and hepatocellular carcinoma. , 2003, Journal of hepatology.

[112]  M. Al-Ahwal,et al.  Chemoembolization in hepatocellular carcinoma. , 1998, Saudi medical journal.

[113]  M. Colombo,et al.  Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.

[114]  G. Kruh,et al.  Doxorubicin and multidrug resistance , 1993, Current opinion in oncology.

[115]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.